UdayR.PopatMD

Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center,

Join to view full profile

Dr. Popat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Popat's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Summary

Uday Popat, MD is a Hematology specialist based in Houston, TX. He completed his Hematology and Medical Oncology fellowship and Internal Medicine residency at Baylor College of Medicine in Houston, after graduating from L. Tilak Municipal Medical College. Dr. Popat's expertise includes stem cell transplantation particularly in patients with acute myeloid leukemia, myelodysplastic syndrome and myelofibrosis. His other major research focus is to improve effectiveness of stem cell transplantation in older patients. He has contributed significantly to the medical literature with a number of published papers and has principal investigator status in several clinical trials.

Education & Training

Baylor College of MedicineResidency, Internal Medicine, 1997 - 1999
L. Tilak Municipal Medical CollegeClass of 1984
Baylor College of MedicineFellowship, Hematology and Medical Oncology

Certifications & Licensure

FL State Medical License 2021 - Present
AZ State Medical License 2023 - 2026
TN State Medical License 2023 - 2026
WA State Medical License 2023 - 2026
GA State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TX State Medical License 2000 - 2025
AL State Medical License 2023 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Fellow (FACP) American College of Physicians, 2005

Clinical Trials

Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation Start of enrollment: 2003 Apr 01
Completed
Not Applicable
High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study Start of enrollment: 2006 Jul 01
Completed
Phase 2
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome Start of enrollment: 2006 Jan 04
Completed
Phase 2
Eltrombopag for Post Transplant Thrombocytopenia Start of enrollment: 2010 Feb 17
Completed
Phase 2
Autologous Transplant in HIV Patients (BMT CTN 0803) Start of enrollment: 2010 Apr 01
Completed
Phase 2
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation Start of enrollment: 2011 Jan 01
Terminated
Phase 1
Allogeneic Transplant in HIV Patients (BMT CTN 0903) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning Start of enrollment: 2012 Apr 11
Completed
Phase 2
Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant Start of enrollment: 2013 Oct 14
Completed
Phase 2
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Start of enrollment: 2014 Oct 27
Active, not recruiting
Phase 2
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation Start of enrollment: 2020 Sep 22
Withdrawn
Phase 2
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS Start of enrollment: 2021 Oct 21
Recruiting
Phase 2
HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 Start of enrollment: 2021 Oct 25
Recruiting
Phase 2
Roles: Contact
Itacitinib for the Prevention of Graft Versus Host Disease Start of enrollment: 2022 Jan 11
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
STRIDE Biorepository Start of enrollment: 2017 Mar 13
Recruiting
Roles: Contact
Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant Start of enrollment: 2017 Jul 30
Active, not recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Start of enrollment: 2024 Sep 30
Not yet recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

30 citations
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Low Left Ventricular Ejection Fraction
Muzaffar H. Qazilbash, Ali Imran Amjad, S. Qureshi, Sofia Qureshi, Rima M. Saliba
Biology of Blood and Marrow Transplantation. 2009-10-01
42 citations
Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Ale...
R. Lamba, George Carrum, G.D. Myers, Catherine M. Bollard, Robert A. Krance
Bone Marrow Transplantation. 2005-11-01
53 citations
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
Borje S. Andersson, Peter F. Thall, Ben C. Valdez, Denái R. Milton, Gheath Alatrash
Bone Marrow Transplantation. 2017-04-01

Journal Articles

Pilot Study Using Post-Transplant Cyclophosphamide (PTCy), Tacrolimus and Mycophenolate GVHD Prophylaxis for Older Patients Receiving 10/10 HLA-Matched Unrelated Donor...
Uday R Popat, Amin Alousi, Issa F Khouri, Muzaffar Qazilbash, Richard E Champlin, Partow Kebriaei, Simrit Parmar, Chitra Hosing, Nature
Impact of a Novel Prognostic Model, Hematopoietic Cell Transplant-Composite Risk (HCT-CR), on Allogeneic Transplant Outcomes in Patients with Acute Myeloid Leukemia an...
Uday Popat, Chitra M Hosing, Issa Khouri, Richard Champlin, Simrit Parmar, Partow Kebriaei, Borje S Andersson, Qaiser Bashir, Amin Alousi, Nature

Abstracts/Posters

Final Results of Phase 2 Clinical Trial of LCL161, a Novel Oral SMAC Mimetic/IAP Antagonist, for Patients with Intermediate to High Risk Myelofibrosis
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Optimal Conditioning for Older Patients with Acute Myeloid Leukemia (AML) Receiving Allogeneic Hematopoietic Stem Cell Transplantation: A Propensity Score Analysis
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Achievement of Complete Remission (CR) with Measurable Residual Disease (MRD) Negativity Is Highly Prognostic in Patients (pts) with Relapsed or Refractory (R/R) Acute...
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A...
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Nonmyeloablative Allogeneic Transplantation (NMAT) Confers an Overall Survival Benefit with Similar Non-Relapse Mortality When Compared to Autologous Stem Transplantat...
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Flurabine Improves Transplant Outcomes in Older MDS Patients
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Post-Transplant Cyclophosphamide (PT-Cy) Based Haploidentical Cell Transplantation (Haplo) Versus Rabbit Anti-Thymocyte Globulin (r-ATG) Based HLA Matched Unrelated Do...
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical Relevance of MYC/BCL2 and Cell of Origin in Patients with Relapsed Diffuse Large B-Cell Lymphoma Treated with Autologous Stem Cell Transplantation
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Randomized Study of Fludarabine-Clofarabine Vs Fludarabine Alone Combined with Busulfan and Allogeneic Hematopoietic Transplantation for AML and MDS
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Hematopoietic Cell Transplantation May Improve Long-Term Outcomes in Patients with Ph-like Acute Lymphoblastic Leukemia with CRLF2 Overexpression
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803...
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Third-Party BK Virus Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Allogeneic Cord Blood Regulatory T Cells Can Prevent Graft Vs. Host Disease and Preserve Graft Vs Leukemia Effect: Update on Phase I/II Clinical Trial
Uday Popat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Reduced Severe aGVHD and Improved Survival Using Post Transplant Cyclophosphamide/Tacrolimus/Methotrexate Graft Versus Host Disease Prophylaxis in AML Patients Receivi...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of...
2019 ASCO Annual Meeting - 6/1/2019
Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Hematopoietic Cell Transplant -Composite Risk (HCT-CR) - a Novel Prognostic Model to Predict Transplant Outcomes
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes: On Behalf of the CIBMTR Ch...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Professional Memberships

American College of Physicians - ACP
Fellow